Nuveen Asset Management LLC Sells 2,025,560 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Nuveen Asset Management LLC reduced its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 30.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 4,552,317 shares of the biotechnology company’s stock after selling 2,025,560 shares during the quarter. Nuveen Asset Management LLC’s holdings in ADMA Biologics were worth $78,072,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ADMA. Perpetual Ltd bought a new position in shares of ADMA Biologics during the fourth quarter worth $62,300,000. Allspring Global Investments Holdings LLC increased its holdings in ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after purchasing an additional 2,613,482 shares in the last quarter. B Group Inc. bought a new position in ADMA Biologics during the 4th quarter worth about $39,231,000. Raymond James Financial Inc. bought a new position in ADMA Biologics during the 4th quarter worth about $19,076,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in ADMA Biologics by 57.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company’s stock worth $47,380,000 after purchasing an additional 1,013,456 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ADMA has been the subject of a number of research reports. Raymond James increased their target price on ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a report on Thursday, May 8th. StockNews.com cut ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday, May 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.25.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $19.69 on Friday. The stock has a market capitalization of $4.70 billion, a price-to-earnings ratio of 70.32 and a beta of 0.57. The business has a 50-day moving average of $20.49 and a 200-day moving average of $18.86. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a fifty-two week low of $9.22 and a fifty-two week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). The company had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. ADMA Biologics’s revenue was up 40.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.08 EPS. As a group, sell-side analysts predict that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.